bluebird bio (NASDAQ:BLUE) Stock Passes Below Two Hundred Day Moving Average – What’s Next?

bluebird bio, Inc. (NASDAQ:BLUE)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $10.29 and traded as low as $6.20. bluebird bio shares last traded at $7.25, with a volume of 286,502 shares changing hands.

Analyst Ratings Changes

Several equities analysts recently commented on BLUE shares. StockNews.com assumed coverage on shares of bluebird bio in a research report on Friday, December 20th. They issued a “sell” rating for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a research note on Friday, November 15th. JPMorgan Chase & Co. cut shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Barclays raised their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 31st. Finally, Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and dropped their price target for the company from $60.00 to $10.00 in a research note on Friday, November 15th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $49.14.

bluebird bio Stock Up 0.3 %

The business has a fifty day simple moving average of $7.93 and a two-hundred day simple moving average of $10.15. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The company has a market cap of $70.66 million, a PE ratio of -0.19 and a beta of 0.68.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Verition Fund Management LLC purchased a new stake in shares of bluebird bio in the third quarter valued at about $42,000. SG Americas Securities LLC boosted its holdings in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares during the period. Barclays PLC increased its holdings in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the last quarter. Finally, Regeneron Pharmaceuticals Inc. purchased a new stake in shares of bluebird bio during the 4th quarter valued at approximately $175,000. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.